



## In Iraqi Polycystic Ovarian Syndrome (PCOS), women are affected by oxidative stress, antioxidants, and a few biological factors

Shaymaa abed hasan<sup>1</sup>

<sup>1,3</sup> Department of gynecology and obstetrics , college of medicine , Al- Iraqia University  
\*Ashaymaa684@yahoo.com

Nora Sabah Rasoul<sup>2</sup>

<sup>2</sup> College of Medicine/ University of Kerbala  
\*Ashaymaa684@yahoo.com

Solafa Rabi Salih<sup>3</sup>

<sup>1,3</sup> Department of gynecology and obstetrics , college of medicine , Al- Iraqia University

### ABSTRACT

PCOS is a heterogeneous complicated ailment with a well-defined etiology that affects the majority of women of reproductive age. The study's purpose is to figure out what PON1 does, Mg, NO, and TAC activity in Iraqi women with PCOS. Eighty samples (40 PCOS patients and 40 controls) were collected between December 2021 and March 2022 for the study. Both groups had their Prolactin, luteinizing hormone (LH), follicle stimulating hormone (FSH), and body mass index (BMI) , fasting blood sugar (FBS), magnesium (Mg), and testosterone levels measured. ELISA was used to measure serum NO (nitric oxide), MDA (malondialdehyde), PON1 activity (paraoxonase 1), and TAC (total antioxidant capacity). When comparing the experimental group to the control group. In PCOS individuals, there was a significant increase in serum levels of LH, Testosterone, and Prolactin, as well as a decrease in serum FSH. Furthermore, FBS levels were considerably higher in PCOS patients, although serum magnesium levels were lower, indicating increased urine excretion of Mg in the presence of insulin. Changes in NO levels in PCOS are highly significant, serum PON1 activity was lower, while TCA was lower in the PCOS group.

### Keywords:

Antioxidant, oxidative stress, polycystic ovary syndrome, Paraoxonase-1

### Introduction

PCOS is a severe public-health issue that affects women of reproductive age and is associated to reproductive, metabolic, and psychological problems. Hyperandrogenism and hirsutism are frequent in PCOS women, as are oligo or amenorrhea and anovulation. Despite a lengthy history of research on PCOS, its cause remains unknown [2].

Nitric oxide (NO) is a very stable gas free radical that diffuses through cell membranes and is a key regulator of vascular

physiology. L-arginine is converted with oxygen and NADPH as cofactors, nitric oxide synthase (NOS) produces NO. NO can have a negative impact on carbohydrates, proteins, and lipids, resulting in cell damage when combined with other inflammatory mediators[2].

Total antioxidant capacity (TAC) refers to serum's ability to limit the generation of free radicals, hence protecting the cell structure from molecular damage [4]. TAC is a level measurement of antioxidant protection

present. This assay evaluates the antioxidant capacity of all of its constituents, such as vitamins, proteins, and lipids [3].

Magnesium is a cofactor of multiple enzymes involved in glucose metabolism, making it necessary for proper glucose use and insulin signaling. Magnesium has been discovered to function as a second messenger in insulin action. Low magnesium levels have been associated to poor glucose tolerance and an increased risk of type 2 diabetes [4].

**Methodology**

A total of eighty samples (40 PCOS patients and 40 controls) were obtained from 25–35 years between December 2021 and March 2022 collected from outpatient clinics. Body mass index (BMI) is computed by multiplying body weight in kilograms by body height in meters squared (kg/m<sup>2</sup>), from all patients. Fasting participant's blood samples were taken to assess fasting FBS, Mg, LH, FSH, Prolactin and testosterone using Cobas E411. The enzyme linked immunosorbent assay (ELISA) method was used to evaluate serum

NO, PON1 activity, and TAC (Mybiosource, USA, Cat.No. MBS732723, MBS705307, MBS726896 respectively).

**Statistical Analysis**

The data was analyzed using the SPSS program version 20.0 software.

**Results**

The results shows of biochemical parameters when comparing between patients and control groups (Table 1). When compared to the control group, PCOS patients had significantly higher serum levels of LH, Testosterone, and Prolactin, as well as a lower serum FSH. FBS levels were also considerably higher in PCOS patients, while Serum magnesium levels were significantly decreased in PCOS patients. Also, highly significantly change in NO levels, in the PCOS group, PON1 activity and TCA levels were lower than in the controls

Table 1 shows the differences in biochemical parameters between PCOS and non-PCOS women.

P_value	S.E	Mean	No.	Sample	Variables
0.805			0.73	27.21 40	patient BMI(kg/m <sup>2</sup> )
				0.77 26.95 40	control
	0.0001		0.40	6.59 40	patient FSH(IU/mL)
				0.22 10.32 40	control
					LH(IU/L)
			0.021	1.15 7.59 40	patient
				0.28 4.81 40	control
	0.001	0.97	10.77	40	patient Testosterone (ng/ml)
				0.27 7.12 40	control
	0.0001	1.37	21.45	40	patient Prolactin (ng/ml)
				0.39 11.65 40	control
	0.0001	3.44	211.14	40	patient FBS (mmol/L)
				3.56 101.11 40	control
	0.0001		0.01	0.35 40	patient Mg (mg/dL)
				0.11 1.43 40	control
	0.001	5.26	107.84	40	patient NO (nmol/ml)
				5.21 81.49 40	control
	0.0001		1.98	38.29 40	patient TAC (U/ml)
				1.51 101.13 40	control
	0.0001	4.95	128.10	40	patient PON1 (U/mL) activity
				6.27 329.38 40	control



linked to a reduction in serum PON1 activity under oxidative stress [19]. Under recent studies, lower serum PON1 activity has been associated to a number of illnesses in oxidative stress and inflammatory settings [20]. There is a lack of research on the oxidative state of PCOS patients. Women with PCOS have been observed to have lower antioxidant levels and experience more oxidative stress [21].

## References

- 1- Neven, A. C. H., Laven, J., Teede, H. J., & Boyle, J. A. (2018, January). A summary on polycystic ovary syndrome: diagnostic criteria, prevalence, clinical manifestations, and management according to the latest international guidelines. In *Seminars in reproductive medicine* (Vol. 36, No. 01, pp. 005-012). Thieme Medical Publishers.
- 2- Simpson, P. V., & Schatzschneider, U. (2016). Small signaling molecules and CO-releasing molecules (CORMs) for the modulation of the cellular redox metabolism. *Redox-Active Therapeutics*, 311-334.
- 3- Apak, R., Özyürek, M., Güçlü, K., & Çapanoğlu, E. (2016). Antioxidant activity/capacity measurement. 1. Classification, physicochemical principles, mechanisms, and electron transfer (ET)-based assays. *Journal of agricultural and food chemistry*, 64(5), 997-1027.
- 4- Santhanam, K. (2020). *Association of serum magnesium deficiency with insulin resistance in type 2 diabetes mellitus* (Doctoral dissertation, Madurai Medical College, Madurai).
- 5- Bacchetti, T., Ferretti, G., & Sahebkar, A. (2019, June). The role of paraoxonase in cancer. In *Seminars in cancer biology* (Vol. 56, pp. 72-86). Academic Press.
- 6- Kiel, I. A., Jones, H., Lionett, S., Røsbjörger, R., Lydersen, S., Vanky, E., & Moholdt, T. (2022). Cardiovascular Health Does Not Change Following High-Intensity Interval Training in Women with Polycystic Ovary Syndrome. *Journal of clinical medicine*, 11(6), 1626.
- 7- Karadeniz, M., Erdoğan, M., Ayhan, Z., Yalcın, M., Olukman, M., Cetinkalp, S., ... & Yılmaz, C. (2011). Effect Of G2706A and G1051A polymorphisms of the ABCA1 gene on the lipid, oxidative stress and homocystein levels in Turkish patients with polycystic ovary syndrome. *Lipids in health and disease*, 10(1), 1-8.
- 8- Türkçüoğlu, I., Engin-Üstün, Y., Turan, F., Kali, Z., Bay Karabulut, A., Meydanli, M., & Kafkasli, A. (2011). Evaluation of asymmetric dimethylarginine, nitric oxide levels and associated independent variables in obese and lean patients with polycystic ovarian syndrome. *Gynecological Endocrinology*, 27(9), 609-614.
- 9- Ergen, K., Yildiz, F., Ozcan, M., Cekmen, M., Ta Utkan, T., & Karakoc, Y. (2012). Oxidative stress status, metabolic profile and cardiovascular risk factors in patients with polycystic ovary syndrome. *Medicine science*, 1(1), 27-34.
- 10- Fathi, F. H. (2020). Biomarkers of oxidative stress in polycystic ovary disorder. *Annals of the College of Medicine, Mosul*, 41(2), 112-116.
- 11- Hilali, N., Vural, M., Camuzcuoglu, H., Camuzcuoglu, A., & Aksoy, N. (2013). Increased prolidase activity and oxidative stress in PCOS. *Clinical endocrinology*, 79(1), 105-110.
- 12- Sulaiman, M. A., Al-Farsi, Y. M., Al-Khaduri, M. M., Saleh, J., & Waly, M. I. (2018). Polycystic ovarian syndrome is linked to increased oxidative stress in Omani women. *International Journal of Women's Health*, 10, 763.
- 13- Aghade, S. M., & Bavikar, J. S. Assessment of glycated hemoglobin and uric acid level in polycystic ovarian syndrome in a Tertiary Care Institute of Marathwada region.
- 14- Rajeswari, G., Veerabhadru, B., & Suresh, E. (2016). Study of magnesium levels in polycystic ovarian syndrome. *Int J App Res*, 2(3), 610-3.

- 15- Ebere, R., Imungi, J., & Kimani, V. (2021). Glycemic index values of traditional Kenyan foods: the missing link in the effectiveness of dietary approach in the prevention and management of diabetes mellitus in Kenya. *African Health Sciences*, 21(2), 710-718.
- 16- Charoengam, N., Shirvani, A., & Holick, M. F. (2019). Vitamin D for skeletal and non-skeletal health: What we should know. *Journal of clinical orthopaedics and trauma*, 10(6), 1082-1093.
- 17- Liew, J. W., Peloquin, C., Tedeschi, S. K., Felson, D. T., Zhang, Y., Choi, H. K., ... & Neogi, T. (2022). Proton Pump Inhibitors and Risk of Calcium Pyrophosphate Deposition in a Population-Based Study. *Arthritis Care & Research*.
- 18- Ahmed M. Mohamadin; Fawzia A. Habib; Thoraya Fadul Elahi (2010). *Serum paraoxonase 1 activity and oxidant/antioxidant status in Saudi women with polycystic ovary syndrome.* , 17(3), 189–196.
- 19- Faverzani, J. L., Hammerschmidt, T. G., Sitta, A., Deon, M., Wajner, M., & Vargas, C. R. (2017). Oxidative stress in homocystinuria due to cystathionine  $\beta$ -synthase deficiency: Findings in patients and in animal models. *Cellular and Molecular Neurobiology*, 37(8), 1477-1485.
- 20- Kotur-Stevuljević, J., Vekić, J., Stefanović, A., Zeljković, A., Ninić, A., Ivanišević, J., ... & Spasojević-Kalimanovska, V. (2020). Paraoxonase 1 and atherosclerosis-related diseases. *BioFactors*, 46(2), 193-205.
- 21- Mancini, A., Bruno, C., Vergani, E., d'Abate, C., Giacchi, E., & Silvestrini, A. (2021). Oxidative stress and low-grade inflammation in polycystic ovary syndrome: controversies and new insights. *International Journal of Molecular Sciences*, 22(4), 1667.